Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
MAPS brings MDMA-assisted therapy training to Poland for the first time, awarding scholarships to 20 practitioners from war-affected Ukraine and Palestine.
 - 
                            
Hod Hasharon, Israel, July 16, 2025 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence...
 - 
                            
XPENG est officiellement entré sur le marché automobile polonais.Le leader chinois des véhicules électriques intelligents a dévoilé 3 modèles : le SUV phare intelligent XPENG G9, le SUV coupé...
 - 
                            
XPENG ist jetzt offiziell auf dem polnischen Automarkt vertreten.Der chinesische Marktführer für intelligente Elektrofahrzeuge hat drei Modelle vorgestellt: das intelligente SUV-Flaggschiff XPENG G9,...
 - 
                            
XPENG Official Launch in Poland – An Electric Automotive Revolution
 - 
                            
BRUSSELS, March 19, 2025 (GLOBE NEWSWIRE) -- WłączeniPlus Foundation's "We Did It In Poland" campaign today announced the premiere launch of the interactive exhibition in Brussels which marked the...
 - 
                            
XPENG appoints Inchcape as distributor and partner for Poland
 - 
                            
WARSAW, Poland, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Since Poland joined the European Union the value of exports of agri-food products has increased: from €5.4 billion in 2004 to €54 billion in 2023,...
 - 
                            
WARSAW, Poland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The White Paper was unveiled on 21 February 2025 at the Medical University of Warsaw during the Health and Security for the Future conference...
 - 
                            
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...